Literature DB >> 11305762

Low-field interventional MRI in neurosurgery: finding the right dose of contrast medium.

M Knauth1, C R Wirtz, N Aras, K Sartor.   

Abstract

MRI is increasingly being used as an interventional tool in neurosurgery. The field strength of "intraoperative" MR systems is usually lower than that of imagers commonly used for diagnostic purposes. However, lesion enhancement and apparent lesion extent depend on field strength. The aim of this study was to compare the contrast between intracranial, contrast-enhancing space-occupying lesions and the surrounding white matter obtained with low-field (0.2 T) and high-field (1.5 T) MR imaging and to find the contrast medium dosage for low-field MRI that produces the same lesion-to-white-matter contrast as the one obtained with high-field MRI after the administration of a standard dose of the contrast medium. A total of 38 patients with intracranial metastases or high-grade glioma were enrolled in this study. T1-weighted spin-echo sequences were acquired. High-field (1.5 T) studies were performed after the i.v. administration of 0.1 mmol gadolinium-DTPA/kg body weight. For low-field MRI (0.2 T) a dose escalation technique was used. T1-weighted sequences were repeated after each of three i. v. injections of 0.1 mmol gadolinium-DTPA/kg body weight. Thus, at the low-field examinations three T1-weighted sequences with a contrast medium dosage of 0.1, 0.2 and 0.3 mmol gadolinium-DTPA/kg body weight were obtained. Lesion-to-white-matter contrasts were calculated and compared. The average lesion-to-white-matter contrast obtained with high-field MR examinations was 1.63 (standard deviation 0.32). In the low-field MR examinations the average lesion-to-white-matter contrast was 1.34 (0.2) after a single dose, 1.57 (0.2) after a double dose, and 1.71 (.19) after a triple dose of contrast medium. The lesion-to-white-matter contrast of the high-field MR examination after a single dose of contrast medium was significantly higher than that of the low-field study after a single dose (P < 0.0001), but did not differ significantly from the low-field studies after a double (P = 0.28) or a triple dose (P = 0.17) of contrast medium. In a series of patients with contrast-enhancing space occupying brain lesions low-field MRI (0.2 T) after a double dose of contrast medium yielded the same lesion-to-white-matter contrasts as high-field MRI (1.5 T) after a standard dose. This is an important finding to avoid errors in intraoperative MRI due to the immanently lower degree of lesion enhancement in low-field MR imaging.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11305762     DOI: 10.1007/pl00006047

Source DB:  PubMed          Journal:  Neuroradiology        ISSN: 0028-3940            Impact factor:   2.804


  6 in total

1.  Theranostic Application of Mixed Gold and Superparamagnetic Iron Oxide Nanoparticle Micelles in Glioblastoma Multiforme.

Authors:  Lova Sun; Daniel Y Joh; Ajlan Al-Zaki; Melissa Stangl; Surya Murty; James J Davis; Brian C Baumann; Michelle Alonso-Basanta; Gary D Kaol; Andrew Tsourkas; Jay F Dorsey
Journal:  J Biomed Nanotechnol       Date:  2016-02       Impact factor: 4.099

Review 2.  Single-dose contrast agent for intraoperative MR imaging of intrinsic brain tumors by using ferumoxtran-10.

Authors:  Matthew A Hunt; Attila G Bagó; Edward A Neuwelt
Journal:  AJNR Am J Neuroradiol       Date:  2005-05       Impact factor: 3.825

3.  Comparing the signal enhancement of a gadolinium based and an iron-oxide based contrast agent in low-field MRI.

Authors:  Jordy K van Zandwijk; Frank F J Simonis; Friso G Heslinga; Elfi I S Hofmeijer; Robert H Geelkerken; Bennie Ten Haken
Journal:  PLoS One       Date:  2021-08-17       Impact factor: 3.240

4.  Dual-Modality Surface-Enhanced Resonance Raman Scattering and Multispectral Optoacoustic Tomography Nanoparticle Approach for Brain Tumor Delineation.

Authors:  Volker Neuschmelting; Stefan Harmsen; Nicolas Beziere; Hannah Lockau; Hsiao-Ting Hsu; Ruimin Huang; Daniel Razansky; Vasilis Ntziachristos; Moritz F Kircher
Journal:  Small       Date:  2018-05-04       Impact factor: 13.281

Review 5.  Multifunctional nanoparticles for brain tumor imaging and therapy.

Authors:  Yu Cheng; Ramin A Morshed; Brenda Auffinger; Alex L Tobias; Maciej S Lesniak
Journal:  Adv Drug Deliv Rev       Date:  2013-09-20       Impact factor: 15.470

6.  A brain tumor molecular imaging strategy using a new triple-modality MRI-photoacoustic-Raman nanoparticle.

Authors:  Moritz F Kircher; Adam de la Zerda; Jesse V Jokerst; Cristina L Zavaleta; Paul J Kempen; Erik Mittra; Ken Pitter; Ruimin Huang; Carl Campos; Frezghi Habte; Robert Sinclair; Cameron W Brennan; Ingo K Mellinghoff; Eric C Holland; Sanjiv S Gambhir
Journal:  Nat Med       Date:  2012-04-15       Impact factor: 53.440

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.